Lixte Biotechnology Holdings, Inc.
LIXT
$5.16
$0.122.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.24% | 145.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.28% | 132.50% | |||
| Operating Income | -1.28% | -132.50% | |||
| Income Before Tax | -28.45% | -155.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.45% | -155.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.45% | -155.30% | |||
| EBIT | -1.28% | -132.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 2.16% | -15.43% | |||
| Normalized Basic EPS | 0.40% | -12.57% | |||
| EPS Diluted | 2.16% | -15.43% | |||
| Normalized Diluted EPS | 0.40% | -12.57% | |||
| Average Basic Shares Outstanding | 28.97% | 126.84% | |||
| Average Diluted Shares Outstanding | 28.97% | 126.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||